[Headaches caused by abuse of symptomatic anti-migraine and analgesic treatment].
These daily or near-daily headaches result from the chronic overuse of all immediate relief antimigraine drugs: ergotamine, analgesics, and/or more recently triptans. Like for much chronic daily headaches, the International Headache Society diagnostic criteria for drug abuse headaches are difficult to apply. Generally, patients confuse primary headaches (usually migraines) with interparoxysmal tension-type headaches called "rebound headaches". Psychosocial factors may play a role. Insidiously, a compulsive automedication results, often in anticipation of headache. This headache syndrome resists symptomatic and prophylactic treatment. These headaches are frequent, very disabling and socioeconomically costly. They are still largely underdiagnosed. Drug-induced headaches may be restricted to those patients who are already headache sufferers. The pathogenesis is not clearly understood: it may involve a deficience of inhibitory pain modulation, a hyperactivation of nociceptive facilitatory systems, and the peripheral and central effects of the incriminating drugs. The withdrawal of all offending analgesic drugs and a multimodality approach are indispensable, but the therapeutic protocoles are actually very heterogeneous and poorly estimated. Non-drug means could be very helpful. Effective education of headache sufferers and regular follow-up are essential to avoid relapses. Prognosis factors have been evoked, but may not be significant for the long term outcome. The rate successfull of is actually estimated at 60 p. cent at five years. The benefits of an adequate management encourage early recognation of drug-induced headaches. This article has in view to take stock of the literature at the end of 1999, and to help physicians become mora aware of this problem and develp a more preventive attitude.
Taïmi
C
C
Centre Anti-Douleur du CHU de Saint-Etienne.
Navez
M
M
Perrin
A M
AM
Laurent
B
B
D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects*; D004879:Ergotamines / Q000008:administration & dosage / Q000009:adverse effects*; D005500:Follow-Up Studies; D006261:Headache / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D010353:Patient Education as Topic; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D019966:Substance-Related Disorders / Q000175:diagnosis*
D000700:Analgesics; D004879:Ergotamines; D017366:Serotonin Receptor Agonists